10 May 2024, Adelaide, Australia: Mayne Pharma Group Limited (ASX: MYX) today announced that the U.S. Patent and Trademark Office has granted US Patent Nos. 11,964,055 (‘055) and 11,957,694 (‘694). The patents, which are US FDA Orange Book listed, provide additional protection to the NEXTSTELLIS® formulation. Both newly listed patents (‘055 and ‘694) will expire June 17, 2036.Mayne Pharma CEO Shawn Patrick O’Brien said: “NEXTSTELLIS® is the flagship product in our Women's Health Portfolio, and we are thrilled about the issuance of these new patents."In addition, Mayne Pharma EVP, Leader of Women’s Health Lynn Sullivan said: “These patents, complement our existing portfolio while enhancing our intellectual property strategy for this differentiated oral contraceptive. NEXTSTELLIS® continues to show the highest growth rate in the US branded OC market.1 We will continue to advance our mission of ensuring that patients have access to this important product.”Licensed from Estetra SRL, a subsidiary of Mithra Pharmaceuticals SA, NEXTSTELLIS® is the first and only contraceptive pill containing a new low impact 2 estrogen, estetrol (E4), and a progestin, drospirenone. E4 is a natural estrogen produced by the human body during pregnancy and in NEXTSTELLIS® it is derived from a plant source. E4 is the first new estrogen introduced in the US in more than 60 years.
Expand
